IPI/R-IPI for Lymphoma Prognosis
The International Prognostic Index (IPI) and Revised International Prognostic Index (R-IPI) predict outcome in aggressive non-Hodgkin lymphoma. R-IPI was updated for rituximab-era treatment.
Warnings:
- IPI was developed for aggressive non-Hodgkin lymphoma (primarily DLBCL)
- R-IPI applies specifically to DLBCL treated with R-CHOP (rituximab era)
- Does not apply to indolent lymphomas or Burkitt lymphoma
- NCCN-IPI uses same factors but with age cutoff at 40 and 75 for more granular risk stratification
- Follicular lymphoma uses FLIPI; mantle cell lymphoma uses MIPI
- 5-year survival percentages are population estimates, not individual predictions
Note: Original IPI (1993): 4 risk groups. R-IPI (2007): 3 risk groups (Very Good=0, Good=1-2, Poor=3-5). NCCN-IPI (2014): Uses 8 score levels (0-8) with cutoffs at 40 and 75 years.
Age at diagnosis
LDH level relative to upper limit of normal
Ann Arbor staging classification
Eastern Cooperative Oncology Group performance status
Number of extranodal disease sites
References
- International Prognostic Index (IPI) and R-IPI for DLBCL - MDCalc - MDCalc (2018)
- A predictive model for aggressive non-Hodgkin's lymphoma - NEJM (International Non-Hodgkin's Lymphoma Prognostic Factors Project) (1993)
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI - Blood (Sehn LH et al.) (2007)
Medical Disclaimer
This calculator is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.